

PRESS RELEASE: Embargoed until November XX at XXh

Inhibiting a protease could improve the treatment of inflammatory bowel disease

- Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease
- The study, published in EMBO Molecular Medicine, shows that blockade of the protease MT1-MMP protects the vasculature in the inflamed gut
- The findings present an important step toward personalized treatment for patients with this condition

Madrid, November xx, 2019. Scientists at the *Centro Nacional de Investigaciones Cardiovasculares* (CNIC) and the *Centro de Investigaciones Biológicas* (CIB) of the *Consejo Superior de Investigaciones Científicas* (CSIC) have identified the protease MT1-MMP as a possible future target for drugs to treat inflammatory bowel disease (IBD). The study was led by Dr Alicia G Arroyo and is published today in *EMBO Molecular Medicine*. The study shows that inhibition of this protease could improve the treatment of IBD.

IBD refers to a group of chronic inflammatory disorders that fall into 2 categories: Crohn disease and ulcerative colitis. Complications associated with these diseases affect the gut (intestinal obstruction, nutrient deficiency, etc.) and other organs (disorders of the skin, joints, eyes, liver and gallbladder, etc.). The appearance of symptoms is unpredictable, and the disease is characterized by periods of remission and relapse. In many patients, symptoms are severe enough to require hospitalization and surgical intervention. Unfortunately, there is currently no universally effective cure for IBD.

During colitis, the intestinal blood vessels duplicate through mechanisms that are poorly understood. In the new study, Dr Arroyo's team used microscopy techniques and 3D image analysis to characterize these duplication events in a mouse model of colitis. These tools enabled the scientists to demonstrate that MT1-MMP expressed on endothelial cells lining the blood vessels impedes their duplication in the inflamed gut, reducing the severity of colitis.



The researchers also investigated the mechanisms underlying vascular duplication during IBD. The first stage in vessel duplication is dilation. One of the most potent vasodilator molecules is nitric oxide, and the authors found that the catalytic activity of MT1-MMP is necessary for nitric oxide production.

To investigate the effect of MT1-MMP on vessel duplication in vivo, the scientists examined the blood vessels supplying the cremaster muscle (covering the testicles and spermatic cord). These vessels are accessible to analysis by intravital microscopy. Using this technique, CNIC researcher Cristina Rius found that the cremaster vessels of mice lacking MT1-MMP did not fully dilate in response to treatment with vasodilators. Similar results were found in blood vessels supplying the intestine.

The authors also found that MT1-MMP 'cuts' the protein thrombospondin-1 (TSP1), generating a TSP1 fragment that binds to the cell adhesion receptor integrin $\alpha\nu\beta3$. The resulting integrin activation triggers the production of nitric oxide, leading to vasodilation and vessel duplication.

This finding has potential clinical implications. "The study shows that patients with mild IBD have higher than normal circulating levels of TSP1, which could be a useful biomarker of the disease," commented Arroyo.

In addition, first author Sergio Esteban described how the team had managed to "reduce vessel duplication in mice with colitis by administering either an antibody that inhibits MT1-MMP protease action or a TSP1 peptide that blocks TSP1- $\alpha\nu\beta$ 3 binding. This result establishes the MT1-MMP-TSP1- $\alpha\nu\beta$ 3 integrin pathway as a new therapeutic target, particularly for less severe forms of IBD."

Finally, the team worked with Fernando Martínez of the CNIC Bioinformatics Unit on a computer model to predict MT1-MMP cleavage sites in TSP1. This model will be used to screen for molecules able to block TSP1 cleavage.

Arroyo concluded that "the study presents a new opportunity to develop personalized treatments not only for patients with IBD, but also for patients with other diseases that progress through vessel duplication, like cancer."

Collaborators in this study include Dr Vicente Andrés' group and the Bioinformatics Unit at the CNIC; Dr Javier P. Gisbert—who provided IBD patient samples—and Dr Ana Urzainqui of the *Instituto de Investigación Sanitaria-Princesa*; and Professor Motoharu Seiki of the University of Tokyo, whose team generated the MT1-MMP reporter mice.

The researchers belong to research networks for cardiovascular disease (CIBER-CV) and liver and digestive diseases (CIBER-EHD) of the *Instituto de Salud Carlos III (ISCIII*



About the CNIC

The Centro Nacional de Investigaciones Cardiovasculares (CNIC), directed by Dr. Valentín Fuster, is dedicated to cardiovascular research and the translation of knowledge gained into real benefits for patients. The CNIC, recognized by the Spanish government as a Severo Ochoa center of excellence, is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 12 of the most important Spanish private companies.



Image 1: Blood vessel duplications in the inflamed intestinal mucosa of a mouse with colitis.

Information and interview requests: Fátima Lois: CNIC Head of Communications. flois@cnic.es / Tel 639282477 Rafael Ibarra: CNIC Communications Office. <u>ribarra@cnic.es</u> / 914531200. Ext 4232